Feb 19 (Reuters) - Traws Pharma Inc TRAW.O:

• TRAWS PHARMA COMPLETES ANALYSIS OF RATUTRELVIR CLINICAL STUDY IN PAXLOVID®-ELIGIBLE AND INELIGIBLE COVID-19 PATIENTS AND PROVIDES UPDATES FOR ADDITIONAL INDICATION FOR TIVOXAVIR MARBOXIL AS A PROPHYLACTIC TREATMENT FOR SEASONAL INFLUENZA

• TRAWS PHARMA INC - FDA PLACES CLINICAL HOLD ON TIVOXAVIR MARBOXIL IND

• TRAWS PHARMA: FDA INTENDS TO COMMUNICATE ITS CONCERNS FORMALLY, TOGETHER WITH SUGGESTED MITIGATION STEPS, BY MARCH 16

• TRAWS PHARMA INC: FDA INTENDS TO COMMUNICATE ITS CONCERNS FORMALLY, TOGETHER WITH SUGGESTED MITIGATION STEPS, BY MARCH 16

• TRAWS PHARMA: FDA PLACED US IND FOR TIVOXAVIR MARBOXIL ON CLINICAL HOLD DUE TO CONCERNS WITH MUTAGENICITY DATA PACKAGE

Source text: ID:nGNXbypyCs

Further company coverage: TRAW.O

((Reuters.Briefs@thomsonreuters.com;))